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Abstract
Background: This practice guideline was developed to provide recommendations to clinicians in
Ontario on the preferred standard radiotherapy fractionation schedule for the treatment of painful
bone metastases.
Methods: A systematic review and meta-analysis was performed and published elsewhere. The
Supportive Care Guidelines Group, a multidisciplinary guideline development panel, formulated
clinical recommendations based on their interpretation of the evidence. In addition to evidence
from clinical trials, the panel also considered patient convenience and ease of administration of
palliative radiotherapy. External review of the draft report by Ontario practitioners was obtained
through a mailed survey, and final approval was obtained from the Practice Guidelines Coordinating
Committee.
Results: Meta-analysis did not detect a significant difference in complete or overall pain relief
between single treatment and multifraction palliative radiotherapy for bone metastases. Fifty-nine
Ontario practitioners responded to the mailed survey (return rate 62%). Forty-two percent also
returned written comments. Eighty-three percent of respondents agreed with the interpretation
of the evidence and 75% agreed that the report should be approved as a practice guideline. Minor
revisions were made based on feedback from the external reviewers and the Practice Guidelines
Coordinating Committee. The Practice Guidelines Coordinating Committee approved the final
practice guideline report.
Conclusion: For adult patients with single or multiple radiographically confirmed bone metastases
of any histology corresponding to painful areas in previously non-irradiated areas without
pathologic fractures or spinal cord/cauda equine compression, we conclude that:
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• Where the treatment objective is pain relief, a single 8 Gy treatment, prescribed to
the appropriate target volume, is recommended as the standard dose-fractionation
schedule for the treatment of symptomatic and uncomplicated bone metastases.
Several factors frequently considered in clinical practice when applying this evidence such as the
effect of primary histology, anatomical site of treatment, risk of pathological fracture, soft tissue
disease and cord compression, use of antiemetics, and the role of retreatment are discussed as
qualifying statements.
Our systematic review and meta-analysis provided high quality evidence for the key 
recommendation in this clinical practice guideline. Qualifying statements addressing factors that 
should be considered when applying this recommendation in clinical practice facilitate its clinical 
application. The rigorous development and approval process result in a final document that is 
strongly endorsed by practitioners as a practice guideline.
Background
Radiotherapy is a well-recognized, effective modality in
the palliative treatment of painful bone metastases. Bone
metastases are a common manifestation of distant relapse
from many types of malignant tumours, especially from
cancers of the lung, breast, and prostate. With the advent
of effective systemic therapies and improvements in sup-
portive care, cancer patients are expected to live longer
and may suffer from metastatic disease for a considerable
length of time. Many patients with bone metastases suffer
from compromised mobility and performance status.
The optimal dose-fractionation schedule for the treatment
of bone metastases is unclear. Two surveys of Canadian
patterns of practice found that various fractionation
schedules are employed by radiation oncologists, ranging
from a single large-dose fraction (e.g., 8 Gy) to a more
prolonged course of 30 Gy/10 fractions over 2 weeks
[1,2]. It has been suggested that the choice of fractiona-
tion is influenced not only by patient-related factors but
also by physician education and attitudes, treatment tox-
icity, resource utilization, and departmental policy [3-7].
While different clinicians may associate "optimal" with dif-
ferent treatment goals, one could recommend that a "pre-
ferred" dose-fractionation is one that provides pain relief
without undue toxicity and is least onerous to the patient.
During the past decade, significant clinical trial efforts
have been devoted to comparing single large-dose radia-
tion (8 Gy to 10 Gy) with multifraction regimens (five to
ten fractions) [8-14]. The two largest trials were published
in 1999 by the Bone Pain Trial Working Party [10] and the
Dutch Bone Metastasis Study group [11]. Results of a
Canadian study were presented at the Canadian Associa-
tion of Radiation Oncologists (CARO) meeting in 2000
and reported in an abstract for the 2000 meeting of the
American Society for Therapeutic Radiology and Oncol-
ogy (ASTRO) [9]. Those randomized trials should provide
substantial evidence to address the question of a "pre-
ferred" fractionation for the majority of patients with
bone metastases.
This provincial guideline was initiated to summarize the
evidence and to provide recommendations on the pre-
ferred standard radiotherapy fractionation schedule for
the treatment of painful bone metastases.
Clinical practice guideline development
This practice guideline was developed by Cancer Care
Ontario's Practice Guidelines Initiative (PGI), using the
methods of the Practice Guidelines Development Cycle
[15]. The practice guideline report is a convenient and up-
to-date source of the best available evidence on the pre-
ferred dose-fractionation of radiotherapy for the treat-
ment of uncomplicated painful bone metastases,
developed through systematic reviews, evidence synthesis,
and input from practitioners in Ontario. The report is
intended to promote evidence-based practice. The PGI is
editorially independent of Cancer Care Ontario and the
Ontario Ministry of Health and Long-term Care. The PGI
has a formal standardized process to ensure the currency
of each guideline report. This process consists of the peri-
odic review and evaluation of the scientific literature and,
where appropriate, integration of this literature with the
original guideline information.
Evidence was selected and summarized by four members
of the Supportive Care Guidelines Group (SCGG) and
methodologists. Members of the SCGG disclosed poten-
tial conflict of interest information, reviewed the analysis
of the evidence, and prepared draft recommendations.
The SCGG includes palliative care physicians, medical
and radiation oncologists, psychiatrists, nurses, psycholo-
gists, a chaplain, an anesthetist, a surgeon, methodolo-
gists, and administrators. After reviewing the evidence and
considering issues of patient convenience and resource
utilization, the SCGG reached consensus on draft recom-
mendations. The systematic review and meta-analysis,BMC Cancer 2004, 4:71 http://www.biomedcentral.com/1471-2407/4/71
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conducted as the initial step in formulating this practice
guideline, has been described elsewhere [16].
External review by Ontario practitioners was obtained
through a mailed survey consisting of items that address
the quality of the draft practice guideline report and rec-
ommendations and whether the recommendations
should serve as a practice guideline. The efficacy of the
practitioner feedback survey process has been previously
described [17]. Final approval of the original guideline
report was obtained from the Practice Guidelines Coordi-
nating Committee (PGCC).
Methods
External review – Ontario practitioner feedback
Practitioner feedback was obtained through a mailed sur-
vey of 95 radiation oncologists across Ontario. The survey
consisted of items evaluating the methods, results, and
interpretive summary used to inform the draft recommen-
dation and whether the draft recommendation should be
approved as a practice guideline. Written comments were
invited. Follow-up reminders were sent at two weeks (post
card) and four weeks (complete package mailed again).
The SCGG reviewed the results of the survey.
Results of practitioner feedback
Fifty-nine of the 95 surveys were returned (62% return
rate). Key results of the practitioner feedback survey are
summarized in Table 1. The survey results indicated that
83% of respondents agreed with the interpretation of the
evidence and 74% agreed with the draft recommenda-
tions as stated. Seventy-five percent of respondents agreed
that the report should be approved as a practice guideline.
Twenty-one respondents (42%) also provided written
comments. The final recommendation was revised to
reflect feedback from practitioners and currently applies
to patients for whom the treatment objective is pain relief.
Practice guidelines coordinating committee approval 
process
The practice guideline report was circulated to PGCC
members for review and approval. Eleven of the fourteen
PGCC members completed and returned ballots. Ten
PGCC members approved the practice guideline report as
written, and one member approved the guideline and pro-
vided suggestions for consideration by the SCGG. Sugges-
tions made were to reword the Target Population section
and to clarify the second qualifying statement. The SCGG
agreed with the suggestions and modified the guideline
accordingly.
Discussion
The preferred radiotherapy dose-fractionation schedule
for the palliation of uncomplicated painful bone metas-
tases has been a controversial subject [18-21]. The goal of
our systematic review was to enable guideline developers
and practitioners to determine whether the available evi-
dence supports the notion of a "standard" dose-fractiona-
Table 1: Practitioner responses to eight items on the practitioner feedback survey.
Item Number (% responders to survey*)
Strongly agree or agree Neither agree nor disagree Strongly disagree or disagree
The rationale for developing a clinical practice 
guideline, as stated in the "Choice of Topic" 
section of the report, is clear.
53 (98) 0 1 (2)
There is a need for a clinical practice guideline 
on this topic.
46 (85) 7 (13) 1 (2)
The literature search is relevant and complete. 51 (94) 3 (6) 0
The results of the trials described in the report 
are interpreted according to my understanding 
of the data.
44 (83) 5 (9) 4 (8)
The draft recommendations in this report are 
clear.
48 (91) 4 (8) 1 (2)
I agree with the draft recommendations as 
stated.
39 (74) 5 (9) 9 (17)
This report should be approved as a practice 
guideline.
39 (75) 5 (10) 8 (15)
If this report were to become a practice 
guideline, how likely would you be to make use 
of it in your own practice*?
Very likely or likely Unsure Not at all likely or unlikely
42 (78) 6 (11) 6 (11)
* may not equal 100 percent due to rounding errorBMC Cancer 2004, 4:71 http://www.biomedcentral.com/1471-2407/4/71
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tion. "Standard" refers to what is applicable to the
majority of patients, with a preference for patient conven-
ience and ease of administration without compromising
treatment efficacy or morbidity. Our meta-analysis of all
published randomized trials found no difference in pain
relief between single fraction and multifraction treat-
ments [16]. Based on this information, the authors of this
practice guideline conclude that a single fraction at 8 Gy is
the preferred standard dose-fractionation for patients with
uncomplicated painful bone metastases. In applying this
evidence into practice, however, the following clinical fac-
tors merit consideration:
1. How durable is the pain relief?
Available evidence does not support the notion that a
more durable response can be achieved with higher dose-
fractionation [11].
2. Is the recommendation appropriate when preventing 
pathological response is an important consideration?
There is a lack of firm evidence relating the fractionation
schedule to the prevention of pathologic fracture because
no study evaluated the risk of pathologic fracture prior to
treatment. Although the pathologic fracture rate was sig-
nificantly higher after single fraction radiotherapy than
after multifraction in the Dutch study [11], the absolute
difference was only 2%. The RTOG study, on the other
hand, showed a higher fracture rate following high dose-
fractionation (40 Gy) than low-dose treatment (20 Gy) in
patients with a solitary metastasis [22]. Until CT (com-
puted tomography)-based bone density measurements
[12] are correlated with pathologic fractures, no evidence-
based recommendation can be given. Patients at risk of
pathologic fractures in long or weight-bearing bones
should be assessed by an orthopaedic surgeon. Where
radiotherapy is considered for tumour downsizing prior
to an orthopaedic procedure or for such patients who are
not surgical candidates, fractionated treatment (e.g., 20
Gy/5 fractions, 30 Gy/10 fractions) would be considered
appropriate by many clinicians. A discussion of fracture
risk assessment is beyond the scope of this review but has
been published elsewhere [23-25].
3. Does the recommendation apply to all pathologies?
It should be noted that the published studies included a
heterogeneous group of patients differing in histologies,
performance status, severity of pain, extent of disease, and
so forth. The fact that breast, prostate, and lung cancer
patients constituted the majority of trial patients implies a
greater confidence in reproducing treatment results for
these patients in practice. However, the evidence does not
provide sufficient materials to allow a recommendation
based on treatment outcomes among subgroups of differ-
ent primary tumours or other patient- and tumour-related
factors.
4. Do treatment field size and anatomical location affect 
application of the recommendation?
The evidence reviewed does not specifically address the
results of large-volume (i.e. wide-field, hemibody irradia-
tion), single fraction treatment. Although average treat-
ment volumes were not reported in any of the single
fraction trials, a significant proportion of patients did
receive treatments to the lumbar spine and pelvis
[10,11,13][Kirkbride P: Personal communications. 2001].
Since treatment volume was not an inclusion or exclusion
criterion among those studies, it is reasonable to assume
that study patients represent the majority of treatment
volumes delivered in an average department. No differ-
ence in nausea and vomiting was seen in the subgroup of
133 patients from the Bone Pain Trial Working Party
study, who were asked to self-assess nausea/vomiting
experience in the first 14 days following treatments [10].
Therefore, the evidence does not support the choice of
fractionated treatment based on volume consideration.
However, the use of prophylactic ondansetron was shown
to significantly reduce vomiting episodes in the single
fraction arm compared with the 20 Gy arm (no prophy-
lactic ondansetron) in the Canadian Bone Mets study
[Kirkbride P: Personal communications. 2001]. For treat-
ment over the epigastrium or lumbar spine, or with larger
treatment volumes in the pelvis, it is reasonable to use a
prophylactic antiemetic, as one would for hemibody irra-
diation. Patients may also be instructed to use anti-
diarrheal agents if enteritis is experienced.
5. Do age and life expectancy affect application of the 
recommendation?
The underlying concern for this group of patients is
whether single large-dose radiation compromises subse-
quent tolerance to re-irradiation. Although no untoward
late effects were reported by the single fraction studies
with follow-up of one year or more [10,11], clinicians
may be uneasy about the long-term effects of repeated
radiation. Given the lack of evidence to the contrary, sin-
gle fraction radiotherapy remains an appropriate treat-
ment option in this subgroup.
6. Does the presence of soft tissue disease around bone 
metastases affect application of the recommendation?
With CT/MRI (magnetic resonance imaging) diagnostic
investigations becoming more routinely available, and
the introduction of the CT-simulator into many depart-
ments, the extent of metastatic disease is likely to be better
evaluated than in the past. In cases where lytic disease is
associated with a large soft-tissue mass (e.g., in the acetab-
ulum and adjacent pelvic bone), the desired palliative
endpoint may be tumour shrinkage as well as pain con-
trol. No evidence-based recommendation can be given for
this scenario.BMC Cancer 2004, 4:71 http://www.biomedcentral.com/1471-2407/4/71
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7. When should re-irradiation be considered?
Re-irradiation may be considered in three scenarios: 1) no
pain relief or pain progression after initial radiotherapy,
2) partial response with initial radiotherapy and the hope
of achieving further pain reduction with more radiother-
apy, and 3) partial or complete response with initial radi-
otherapy but subsequent recurrence of pain. The response
after re-irradiation may be different for each of these sce-
narios. Two published studies reported response rates to
re-irradiation [26,27] with doses ranging from 4 Gy as a
single dose to 30 Gy in 10 fractions over two weeks. The
Dutch Bone Metastases Study [11] was re-analyzed to sep-
arate the response to initial treatment from the response
to re-treatment. Van der Linden presented the results at
the 2003 ASTRO meeting [28]. The majority of the 173
patients re-irradiated received single fraction 8 Gy as the
initial treatment. Overall response rate to re-treatment
was 63%. At present no clear guideline can be given
regarding dose-fractionation of re-irradiation. A new
intergroup randomized trial supported by the National
Cancer Institute of Canada (NCIC) of single versus multi-
ple fractions for re-irradiation opened in January 2004
and is expected to accrue patients from Canada, the
United Kingdom, the Netherlands, and Australia [29].
8. How is radiation-induced emesis best managed when 
delivering spinal irradiation?
No increase in acute gastrointestinal morbidity was
observed with single fraction treatment compared to mul-
tiple fractions. The Canadian study showed significantly
fewer vomiting episodes with single fraction treatment
after prophylactic ondansetron was used in cases with
treatment fields over the abdomen or pelvis [Kirkbride P:
Personal communications. 2001]. Antiemetic agents
should be considered as a prophylaxis, given that 30% or
more of patients experienced vomiting following single or
multifraction treatment in the two studies that specifically
collected patient-assessed nausea/vomiting data [9,10].
Conclusions
For patients where the treatment objective is pain relief, a
single 8 Gy treatment, prescribed to the appropriate target
volume, is recommended as the standard dose-fractiona-
tion schedule for the treatment of symptomatic and
uncomplicated bone metastases. This recommendation
applies to adult patients with single or multiple radio-
graphically confirmed bone metastases of any histology
corresponding to painful areas in previously non-irradi-
ated areas without pathologic fractures or spinal cord/
cauda equina compression. It does not apply to the man-
agement of malignant primary bone tumour. The follow-
ing qualifying statements are provided to support the
application of the recommendation in clinical practice:
• "Standard" refers to what is applicable to the majority of
patients, with a preference for patient convenience and
ease of administration and without compromising treat-
ment efficacy or morbidity.
• The recommendation does not apply to lesions previ-
ously irradiated, or lesions causing cord compression or
pathologic fractures, because such patients were mostly
excluded from clinical trials examining fractionation
schedules.
• Prophylactic antiemetic agents should be considered
when a significant proportion of the gastrointestinal tract
is in the irradiated volume.
• Patients and referring physicians should be advised that
repeat irradiation to the treated area may be possible.
• There is insufficient evidence at this time to make a dose-
fractionation recommendation for other treatment indi-
cations, such as long-term disease control for patients
with solitary bone metastasis, prevention/treatment of
cord compression, prevention/treatment of pathologic
fractures, and treatment of soft tissue masses associated
with bony disease.
This practice guideline incorporates recommendations
based on a systematic review, comprehensive considera-
tion of how the evidence may be applied to clinical prac-
tice, feedback from Ontario practitioners, and input from
the Practice Guidelines Coordinating Committee prior to
final approval. It is strongly endorsed by practitioners for
whom it was developed.
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